Related Experiment Videos
Nutrition support for glutaric acidemia type I
S Yannicelli1, F Rohr, M L Warman
1Ross Laboratories, Columbus, Ohio 43215.
Journal of the American Dietetic Association
|February 1, 1994
Summary
Early dietary intervention restricting lysine and tryptophan, alongside riboflavin and L-carnitine, may halt neurologic damage in glutaric acidemia type I. This approach shows promise for affected children.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- Glutaric acidemia type I (GA-I) is an inherited metabolic disorder affecting lysine and tryptophan breakdown.
- A deficiency in glutaryl-coenzyme A dehydrogenase leads to toxic glutaric acid accumulation.
- Untreated GA-I often results in severe, progressive neurological damage and mortality.
Purpose of the Study:
- To review existing literature on dietary and pharmacologic therapies for GA-I.
- To establish evidence-based guidelines for nutritional support in GA-I.
- To present findings from treating four children with GA-I.
Main Methods:
- Literature review of published dietary and pharmacologic interventions for GA-I.
- Analysis of treatment outcomes in four pediatric patients with GA-I.
- Development of nutrition support guidelines based on clinical experience.
Main Results:
- Dietary restriction of lysine and tryptophan, combined with riboflavin and L-carnitine, may prevent or slow neurological deterioration.
- Children diagnosed and treated early, before neurological damage, have shown normal growth and development.
- The study provides practical guidelines for managing nutrition in GA-I patients.
Conclusions:
- Dietary restriction of lysine and tryptophan is a safe and potentially effective therapy for GA-I.
- Early intervention is crucial for preventing irreversible neurological sequelae in GA-I.
- Comprehensive management involving diet and supplements is recommended for individuals with GA-I.